Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data 26-10-2023, 15:00

Olaplex Holdings, Inc. to Report Fourth Quarter and Fiscal 14-02-2023, 18:54